SBIR/STTR Research Award
AIRWAY PERFUSION ASSISTED LIQUID VENTILATOR
Award amount
$0Program and phase
STTR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MALLARD MEDICAL CO., INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): We have developed and patented (U.S. Pat
No. 5,706,830) a new type of closed circuit perfluorocarbon (PFC) liquid
ventilator with enhanced capabilities for gas exchange and exudates clearance
from the lungs. This system has potential application to rescue of patients in
acute respiratory failure and treatment of cystic fibrosis. The system employs
a continuous isovolumetric perfusion (bias flow) of oxygenated PFC through one
lumen of a double lumen endotracheal catheter that is superimposed on tidal
liquid ventilation (liv). Phase I studies in newborn piglets indicate that bias
flow significantly improved blood gases and increased the clearance of a five
percent albumin solution from the lung by over 3-fold. During Phase II we
propose to finalize the prototype design and control system software for
ventilatory parameters and a feedback control of lung liquid volume based on
measurements of end-expiratory stop-flow pressures. High performance pulseless
pumps, an oxygenator and vapor recovery system will be included as well as
protective algorithms and relief valves to limit airway pressure excursions.
Phase II experimental studies in piglets and rabbits will examine novel
applications of TLV with bias flow for sustaining arterial blood gases during
oleic acid lung injury, increasing the clearance rate of five percent albumin
solution and mucus-like gels from the lung, and enhancing the homogeneity of
gene expression for a reporter gene introduced during TLV. We will also apply
for an Investigational Device Exemption (IDE) from the Food and Drug
Administration during Phase II to distribute ventilator prototypes to research
institutions.
PROPOSED COMMERCIAL APPLICATION:
This liquid ventilator will be used in infant and adult intensive care units to treat end-stage respiratory failure as a lower cost alternative to extracorporeal oxygenation. Other applications include continuous intrapulmonary administration of drugs and anesthetics and clearance of material from the lungs.
Technology keywords
Not reported